targeted cancer therapy

Targeted cancer therapy is a precision medicine approach that inhibits specific molecules, proteins, genes, or pathways in cancer cells to block growth, spread, or survival, minimizing damage to healthy cells compared to traditional chemotherapy, according to specialists like Ecaterina Dumbrava, M.D., at UT MD Anderson focused on specific molecules. It serves as the foundation of precision oncology, tailoring treatments to a patient's tumor genetics via molecular testing testing for mutations, with drugs recommended based on identified targets like HER2 in breast cancer HER2 in breast cancer, EGFR mutations in lung cancer EGFR for lung cancer, or enzymes in leukemia enzymes in leukemia. Types include small molecule drugs taken as pills small molecule drugs, hormone therapies for breast/prostate cancers hormone therapies, angiogenesis inhibitors starving tumors of blood vessels angiogenesis inhibitors, and proteasome inhibitors for multiple myeloma proteasome inhibitors. Administered as pills or IV pill or IV, it offers hope for advanced cancers or those with mutations like in CML CML mutation or BRAF V600E BRAF combination, with FDA approvals for breast, lung, colorectal, and melanoma FDA approvals. However, tumors can develop resistance through alternative pathways resistance mechanisms, not all patients have targetable mutations not for all, and side effects include skin issues, diarrhea, high blood pressure, and organ damage like thyroid thyroid damage, heart problems heart problems, or peripheral neuropathy peripheral neuropathy. Monitoring uses scans and blood tests monitoring progress, with ongoing research into combinations and new targets like TP53, per MD Anderson and Winship Cancer Institute.

Targeted cancer therapy, also known as precision or personalized medicine, involves drugs that interfere with specific molecules, proteins, or genetic mutations driving cancer growth, progression, and spread, tailoring treatment to a patient's tumor genetics (targeted therapies definition), (personalized to tumor), (precision medicine synonym). Unlike traditional chemotherapy, which indiscriminately kills fast-dividing cells including healthy ones like hair follicles and blood cells, targeted therapies attack mutated proteins in cancer cells while sparing most normal cells, as stated by Ecaterina Dumbrava, M.D. (specific molecules focus), (vs chemotherapy sparing cells). Doctors identify suitable drugs via genetic testing or biomarker testing on tumor cells to find actionable mutations (genetic tests for drugs), (biomarker testing process). These therapies target mutations like BRAF, BRCA1/2, EGFR, HER2, KRAS (specific mutations treated) and fusions like ALK, ROS1 (gene fusions addressed), treating cancers including breast, lung, colorectal, melanoma, leukemia (cancers treated list). Types include small molecule drugs entering cells (small molecule drugs), monoclonal antibodies targeting surface molecules (monoclonal antibodies type), tyrosine kinase inhibitors (TKIs block kinases), angiogenesis inhibitors, and hormone therapies. Administered as pills at home, IV infusions, or injections (administration methods), treatment duration varies from fixed periods to lifelong or until resistance develops (varying treatment duration). Often combined with chemotherapy, immunotherapy, or radiation for better outcomes (combination treatments). Side effects include fatigue, diarrhea, skin issues, and serious ones like heart problems, partly because targets exist in normal cells (common side effects), (side effects from normal cells). Resistance arises via new mutations or alternative pathways, addressed by re-testing, alternatives, or trials; Memorial Sloan Kettering Cancer Center researches solutions (drug resistance common), (MSK resistance research). Mechanisms include blocking signals, inducing apoptosis, synthetic lethality, or immune enhancement.

Targeted cancer therapy functions by targeting specific characteristics of cancer cells, akin to a specialized weed killer that spares healthy cells targets specific cancer traits. Small-molecule drugs are taken orally as pills or capsules oral small-molecule administration, while monoclonal antibodies are given intravenously IV monoclonal antibodies; treatments occur at home, clinics, or hospitals, often in cycles with rest periods various administration settings. Doctors monitor effectiveness via exams, blood tests, and scans monitoring via tests and scans. Side effects include blood clotting issues, high blood pressure, fatigue, skin rashes, diarrhea, and rare gastrointestinal perforations, though most resolve post-treatment and medicines can mitigate them common side effects listed. Ecaterina Dumbrava from UT MD Anderson Cancer Center notes targeted therapies significantly improve outcomes, prolong survival, and maintain quality of life, with some hospice-bound patients achieving long-term success Dumbrava on improved outcomes. However, it suits not every patient due to lacking targetable mutations, offers no guarantees like chemotherapy, and proves costly not suitable for all patients. Emerging types include antibody drug conjugates delivering chemo to tumors antibody drug conjugates emerging; resistance to PARP inhibitors is addressed by combining with other targeted therapies. Phase I trials determine dosing and side effects, with trials accessible via NCI searches and conducted worldwide Phase I trial purposes. Dumbrava highlights rapid advances like KRAS targeting and future TP53 potential; foundational concepts from Torti D and Trusolino L (2011) on oncogene addiction underpin it, as do prostate cancer advances by Hernando Polo S et al. (2021).